Consistent adherence to scheduled anti-VEGF treatment is crucial for preserving and improving vision in patients with neovascular age-related macular degeneration (nAMD), according to a study.
Researchers analyzed real-world data from patients aged 50 and older who began anti-VEGF therapy and completed 12 months of follow-up.
Among the 133 patient eyes studied, 129 were classified as adherent to treatment, while only 4 were non-adherent. Adherence was defined as having <20% of clinic visits delayed by 14 days or more. Patients who followed their injection schedule closely showed a mean visual acuity improvement of 6.3 letters after 1 year. In contrast, those who missed or delayed appointments experienced a decline of 11 letters.
Reference
Shellvarajah M, Nguyen V, Steinmann S, et al. Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study. Ophthalmol Ther. 2025;doi: 10.1007/s40123-025-01140-z. Epub ahead of print. PMID: 40232637.
Related Content
